Target intelligence / Profile preview

Formyl peptide receptor 3 (FPR3) (FPR3)

Target
FPR3
Molecular classification
G protein-coupled receptor, Rhodopsin-like GPCR, Formyl peptide receptor family
01

Overview

Formyl peptide receptor 3 (FPR3), also known as Formyl peptide receptor-like 2 (FPRL2), is a G protein-coupled receptor (GPCR) that is part of the formyl peptide receptor family. Unlike FPR1 and FPR2, FPR3 is primarily expressed on monocytes, macrophages, and dendritic cells, and it does not respond to the classical bacterial peptide N-formylmethionyl-leucyl-phenylalanine (fMLF). Instead, it is activated by endogenous ligands such as the peptide F2L, which is derived from the heme-binding protein. Activation of FPR3 triggers intracellular calcium mobilization and chemotaxis, playing a significant role in the recruitment and maturation of myeloid cells during the immune response. Because of its involvement in leukocyte trafficking and inflammatory signaling, FPR3 is a potential therapeutic target for inflammatory and autoimmune diseases. However, the high structural similarity between FPR family members poses a challenge for the development of selective pharmacological agents (Source: UniProt P25090; IUPHAR/BPS Guide to Pharmacology).

Other names
Formyl peptide receptor-like 2FPRL2FMLP-related receptor IIFMLP-R-IIHM63
02

Mechanism of action

FPR3 acts as a G protein-coupled receptor that, upon ligand binding, couples to Gi proteins to inhibit adenylyl cyclase activity and stimulate phospholipase C, leading to increased intracellular calcium levels and activation of MAP kinase pathways. This signaling cascade promotes chemotaxis and the functional activation of monocytes and dendritic cells (Source: UniProt P25090; PMID: 11781383).

03

Biological functions

ChemotaxisImmune responseSignal transductionCalcium mobilizationMyeloid cell maturation
04

Disease associations

InflammationAutoimmune diseaseInfectionCancer
05

Safety considerations

Off-target effects due to high homology with FPR1 and FPR2Potential for broad immunosuppressionRisk of increased susceptibility to infection
06

Interacting drugs

F2L

4 more in the full profile.

07

Biomarkers

FPR3 surface expression on CD14+ monocytesFPR3 expression on plasmacytoid dendritic cellsF2L peptide levels in plasma

Beyond the preview

Go deeper on Formyl peptide receptor 3 (FPR3) (FPR3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Formyl peptide receptor 3 (FPR3) (FPR3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call